Profile of Coagulation Marker and The Influence Factors in Central Nervous System Tumor

Yunni Diansari; Mediarty Syahrir; Sri Novianty Yusuf

doi:10.32539/mks.v53i2.10065

Profile of Coagulation Marker and The Influence Factors in Central Nervous System Tumor

Yunni Diansari, Mediarty Syahrir, Sri Novianty Yusuf

Abstract

Brain tumors have the highest percentage of thrombosis compared to other types of malignancies. Hypercoagulation is a risk for thromboembolic events in patients with malignancy. Hypercoagulation conditions are frequently found in patients with malignancy arising from the aptitude of tumor cells to activate the coagulation system. This condition can be detected through coagulation markers in the blood. This marker is PT, APTT, INR, Fibrinogen and D-Dimer. This research is a descriptive analytic study using secondary data from medical records of patients with central nervous system (CNS) tumors. The inclusion criteria were CNS tumor patients > 18 years old and had been diagnosed with CNS tumor. Coagulation markers are recorded based on the results of the initial laboratory examination upon entering the hospital, consisting of D-Dimer, PT, APTT, Fibrinogen, INR. There were 124 research subjects, consisting of 60 men and 64 women. Most research subjects are in the age range of 40-49 years (54.8%). Hypercoagulation conditions were found in 92.74% of study subjects. The most common accompanying condition was hypertension (22.6%). There were no significant differences in the hypercoagulable conditions in groups with and without accompanying conditions. Hypercoagulation was found in most research subjects. There are no factors that influence the hypercoagulation condition in this study.

Keywords

hypercoagulation, accompanying conditions, coagulation markers, CNS tumors

Full Text:

PDF

References

Cancer Statistic Facts: Brain and Other Nervous System Cancer. National Cancer Instute of Heath. 2014.

Elyamany G, Alzahrani AM, Bukhary E. Cancer-associated thrombosis: an overview. Clinical Medicine Insights: Oncology. 2014;8:129-37.

Roberts, Lara N, MBBS, MD, Arya Roopen, BMBCh. Best Practice. Hypercoagulation state. BMJ Publishing Group. 2018.

Hawbaker S. Venous thromboembolism in the cancer population: pathology, risk, and prevention. Journal of The Advance Practional in Oncology. 2012;3(1):23-33.

Jain S, Harris J, Ware J. Platelets: Linking hemostasis and cancer. Arterioscler Thromb Vasc Biol. 2010;30(12):2362-7.

Blann AD, Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiology Research and Practice.2011;394740.

Suega K, Bakta IM. Correlation between clinical stage of solid tumor and D dimer as a marker of coagulation activation. Acta Medica Indonesia. 2011;43(3):162-67.

Aishiama K, Yoshimoto Y. Screening strategy using seqeunsial serum D-dimer assay for detection and prevention of venous thromboembolism after elective brain tumor surgery. British Journal of Neurosurgery. 2013;27(3):348-54

Jenkins EO, Schiff D, Mackman N, Key NS. Venous thromboembolism in malignant gliomas. Journal of Thrombosis and Haemostasis. 2010;8(2):221-27.

Van Zaane B, Nur E, Squizzato A, Gerdes VE, Buller HR, Dekkers OM, Brandjes DP. Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. Journal of Thrombosis and Haemostasis. 2010;8(11):2483-93.

Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Review of Clinical Pharmacology. 2011;4(2):233-42.

Kostaras X, Cusano F, Kline GA, Roa W, Easaw J. Use of dexamethasone in patients with high-grade glioma: A clinical practice guideline. Current Oncology. 2014;21(3):493-503

Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K. Glucorticoid supress tumor angiogenesi and in vivo Growth of Prostate Cancer Cell. Clin Cancer Res 2006;12:3003-3009.

Eppy HA, Amin Z, Nainggolan G, Atmakusuma D. Hiperkoagulasi pada Pasien Kanker Paru bukan Sel Kecil. Maj Kedokter Inon; 57;2.2007

Goldschmidt N, Linetsky E, Shalom E, Varon D dan Siegal T. High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer. 2003. Vol 98. No 06.

Mari D, Ogliari G, Castaldi D, Vitale G, Bollini E M, Lio D. Hemostasis and ageing. Immunity and ageing 2008. 5;12.

Norbaini AR, Jones G, Bhandari M, C. Berndt M, Metharom P. Cancer associated thrombosis: An overview of mechanisms, risk factors, and treatment. Cancers. 2018.

Zhang Y, Yang Y, Chen W, Liang L, Zhai Z, Guo L, Wang C, China VTE group. Hypertension associated with venous thromboembolism in patients with newly diagnosed lung cancer. Scientific reports. 2016

Tapson, V F. The Role of Smoking in Coagulation and Thrombomembolism in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc. Vol 2. Pp 71-77. 2005

Setiawan A, Pudjanarko,Tugasworo D. Pengaruh Pemberian Deksametason Terhadap Kadar D Dimer Plasma pada Pasien Tumor Otak. Medica Hospitalia. 2015;3(1):25–31.

DOI: https://doi.org/10.32539/mks.v53i2.10065